Periodic Reporting for period 2 - hPSCreg (Human Puripotent Stem Cell Registry)
Reporting period: 2018-07-01 to 2019-12-31
It the most accepted and complete hPSC-registry and invaluable resource of cell lines and their application and developing and promoting standards and guidelines. In addition, the Registry reduces risks in the field by enabling comparability and reproducibility, as well as avoiding waste of resources by providing access to hPSC-lines worldwide. The Registry is also instrumental in promoting quality standards of lines. Substandard lines will not be accepted for use by the community, while lines in hPSCreg fulfill a validated standard. Hence, the hPSCreg is a global hub for hPSC data and information.
The objectives of the project are driven by the needs for a comprehensive public information source for pluripotent stem cells, as outlined in the call: to gather and make available detailed information on the different hPSC lines derived in Europe and beyond, thereby also avoiding needless creation of new cell lines. This registry operates through an internet website that will continue to provide high quality data about the lines (e.g. cell characteristics), details regarding their source and contact information regarding their location.
The objectives are divided into the main concept areas (i) acquisition, registration and qualification of information, (ii) communication, dissemination and harmonization, (iii) technical implementation, governance and project management. The specific objectives are (1) Provision of validated ethics information for each cell line, (2) Provision of validated scientific information for each cell line, (3) Provision of information on clinical application of hPSC lines, (4) Establish and strengthen international reach and community interaction as well as acceptance, (5) A stable state of the art back- and frontend must be established and maintained and (6) Implement a synergistic management structure supported by clear governance tasks.
1. The Registrie's unique ethics data model was finalized and a version for data output and searchability developed with community input. An unpdated interface for ethics data comparison and searchng is being devised.
2. Cell line registration is a continuous task to increase the number of lines, and their data quality, in hPSCreg. The registration data model was improved and implemented. The number of registered hESC-Lines increased from 797 by 06/2018 to 1335 by 12/2019 and of hiPSC-lines in this period from 788 to 4494. The number of registered projects using hPSC lines increased also from 110 to 160.
3. Clinical use of hPSC will be the next revolution in cell therapy. Therefore, hPSCreg developed a data model for clinical grade hPSC lines and implemented a dedicated database as part of the registry. The beta (test) Version is currently being tested and by registered users for finalization.
4. Cölinical study database: hPSCreg developed a data model for the registration of pluripotent stem cell based clinical studies. The database is active in hPSCreg and presents the most comprehensive database for hPSC - based clinical studies, with 50 clinical studies registered: hESC (n=27), hiPSC (n=19) and parthenotic PSC (n=4).
5. The Registry has expanded ist global outreach by collaborating with EBiSC, ISCBI, GAiT, SKIP, ICTAC, GSCN, CAS and several other banks and initiatives in the USA and Asia.
5. We set up social media tools (Twitter, Youtube) and a feedback and commentary option in hPSCreg. We have authored and co-authored several publications and presented hPSCreg at 15 international conferences and Meetings.
6. The Registry team provided and maintained an accurate, safe and carefully constructed database (backend) and portal (front end) as a continous task, which fully complies with GDPR. An adequate management structure and relevant documentation of the code and of all Registry related administrative documents was implemented; governance documents are publicly accsssible.
7. More than 160 research projects are registered in hPSCreg (up from 110);192 Cell - line certificates were issued (up from 91).
hPSCreg provides companies with a tool to help reduce risk to commercial development by cell selection through availability of qualified ethics and scientific data. The hPSCreg data model also serves as basis for EBiSC, StemBancc and other resources and the lines are accessible through hPScreg.
The Registry provides direct access to ethics provenance information. This is unique and allows assessment of suitability from an ethical point of view. In addition, hPSCreg issues certificates, which verify that a line adheres ethically and scientifically to the highest standards, based on the submitted data. These certificates are required for funding for example by the EC. hPSCreg serves as a reviewer for publication in the journal Stem Cell Research – Lab Resource by validating submitted data on hPSC – lines.
Stem cell technology has significant potential to improve human health with huge economic potential. In providing an international coordination activity and best practice, hPSCreg impacts stem cell-based industries and increase their competiveness by supporting standards and harmonization, comparability and selection of the most effective protocols and cell lines.
hPSCreg's advantage for sustainability is based on a comprehensive, inclusive database hosting the world’s largest collection of validated hPSC lines. However, expanding and improving EU-hPSCreg activity is critical to providing the required international exposure to consolidate its efforts in the new and challenging area of hPSC products. The increased impact of hPSCreg is key to assure sustainability.